The global protein expression market, valued at US$3.34 billion in 2023, reached US$3.41 billion in 2024 and is projected to grow at a resilient compound annual growth rate (CAGR) of 7.1% through 2029. By the end of the forecast period, the market is expected to reach a valuation of US$4.82 billion. This expansion is primarily driven by the increasing demand for biologics, rising R&D investments in the pharmaceutical and biopharmaceutical sectors, and the integration of artificial intelligence and machine learning to enhance protein-based studies.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180323924
What are the key drivers influencing the growth of the Market?
The primary driver for the protein expression market is the increasing demand for biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and vaccines. These therapies are essential for treating cancer, autoimmune diseases, and chronic inflammatory conditions. In 2023 alone, the US FDA approved 17 new biologics, 12 of which were monoclonal antibodies, highlighting a strong regulatory environment that supports market expansion. There is a growing need for high-performance expression systems to meet the large-scale manufacturing requirements of these complex therapeutic products.
Additionally, advancements in technology, specifically the use of artificial intelligence (AI) and machine learning (ML), are significantly enhancing protein expression workflows. These tools improve protein structure prediction and optimize expression systems, increasing overall research productivity. The market is also bolstered by a rising trend in personalized and precision medicine, as well as the increasing practice of outsourcing clinical research and drug development activities to specialized organizations.
What are the major restraints limiting the growth of the Market?
A significant restraint is the renewed industry focus on small molecule-based drug development. Small molecules are often preferred by pharmaceutical companies because they are generally more affordable to produce, easier to administer to patients, and have broader therapeutic applications. In 2023, more than half of the 55 new drugs approved by the US FDA were small molecules, indicating a strong industry preference that can divert R&D investments away from protein-based biologics.
The high cost of protein expression offerings also acts as a barrier to market growth. These costs can limit the accessibility and adoption of advanced expression technologies, particularly for smaller biotech firms or institutions with restricted budgets. This financial pressure, combined with the competitive landscape of drug modalities, can dampen the overall growth potential of the protein expression sector.
What emerging opportunities are expected to shape the future of the Market?
The growing emphasis on plant-based and cell-free expression systems represents a major growth opportunity. Traditional mammalian and bacterial systems often face scalability and protein folding challenges; however, plant-based systems offer higher efficiency and lower infrastructure costs by simply increasing cultivation. These systems are also more environmentally sustainable, as they consume less energy and recycle water. Cell-free expression (CFPE) methods provide further flexibility and higher yields for complex proteins requiring specific modifications, as demonstrated by platforms like Alice by LenioBio.
Advancements in synthetic protein production technologies also offer potential for market expansion. As industries beyond healthcare, such as agriculture and cosmetics, begin to apply protein optimization and synthesis, the demand for innovative expression platforms is expected to rise. Furthermore, major players are increasingly establishing manufacturing and research facilities in emerging economies, tapping into new geographic markets and expanding their global footprint.
What are the critical challenges faced by stakeholders in the Market?
Stakeholders face significant challenges related to production costs and efficiency issues inherent in current expression systems. Bacterial systems, while cost-effective, often produce insoluble aggregates called inclusion bodies that complicate the purification process and reduce final yields. Conversely, while mammalian systems are better suited for producing complex proteins, they suffer from high labor costs and lower expression levels compared to microbial systems.
There are also technical hurdles regarding post-translational modifications, which are essential for proper protein function but are not easily achieved in all systems. Additionally, plant-based systems face regulatory and safety concerns regarding the potential spread of recombinant genes into the food chain. Downstream processing and achieving low-cost commercial scalability remain persistent difficulties that challenge the large-scale manufacturing of therapeutic proteins.
Who are the leading players operating in the Market?
The global protein expression market is characterized by several dominant players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Agilent Technologies, Inc. (US). These companies provide a wide range of protein expression products and services and are actively involved in strategic acquisitions, such as Thermo Fisher’s acquisition of Olink Holding AB and Merck’s acquisition of Mirus Bio, to strengthen their bioprocessing portfolios.
Other significant contributors to the competitive landscape include Danaher Corporation (US), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), and Lonza (Switzerland). Additionally, companies like GenScript (US), Takara Bio Inc. (Japan), and Qiagen (Netherlands) play vital roles in providing specialized reagents and instruments. The market also features emerging participants from the Asia Pacific region, such as Sino Biological, Inc. (China) and Syngene International Limited (India), who are expanding their presence in the global supply chain.
What are the key segments of the Market based on type, application, and end user?
Based on workflow, the market is led by the extraction, purification, and characterization segment, which held the largest share in 2023. This phase is critical as the final stage of production, involving isolation and verification of the expressed proteins using expensive specialized reagents and instruments. By expression system, the market includes mammalian, bacterial, yeast, plant-based, and cell-free systems, with mammalian systems being widely used for complex biologics.
In terms of end users, pharmaceutical and biotechnology companies accounted for the largest market share in 2023, driven by the rising approval of protein-based drugs and increased R&D for chronic disease therapies. Other key end-user segments include academic and research institutes, as well as CROs and CDMOs. Application-wise, the market is categorized into therapeutic proteins, vaccines, and diagnostics, with therapeutic applications dominating due to the high demand for monoclonal antibodies.
Which regions are dominating and emerging in the Market?
North America currently dominates the protein expression market and is expected to maintain its leading position through the forecast period. This dominance is supported by a high concentration of major pharmaceutical and biotechnology companies, prominent academic research institutions, and substantial government funding for protein-based therapies. The region also benefits from a high prevalence of chronic diseases like cancer, which necessitates advanced treatment options.
The Asia Pacific region is expected to witness the fastest growth during the forecast period. This upward trend is driven by the increasing trend of outsourcing clinical research and drug development activities to countries like China and India. Growing investments in healthcare infrastructure and the establishment of new manufacturing facilities by global players in these emerging economies further support the rapid expansion of the protein expression market in this region.
Inquire Before Buying-https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=180323924
